Literature DB >> 11920463

Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.

Nicholas J Shaheen1, Walter L Straus, Robert S Sandler.   

Abstract

In multiple studies, the chronic use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a decreased incidence of several types of gastrointestinal (GI) neoplasia. This effect may be mediated by one of several intracellular mechanisms, some of which involve the inhibition of the cyclooxygenase-2 (COX-2) isoenzyme. In multiple studies of colorectal carcinoma, chronic NSAID use has shown a protective effect, with the majority of studies demonstrating a 30-70% risk reduction associated with NSAID use. The effect of NSAIDs on other types of GI neoplasia is less clear, but evidence suggests that chronic NSAID use may diminish the risk of esophageal and gastric carcinomas. Data assessing the effects of NSAIDs on the incidence of pancreatic and hepatic malignancies currently are too sparse and inconsistent to draw any conclusions. The newer COX-2 specific agents may provide a less GI-toxic alternative to nonselective NSAIDs as chemoprotective agents. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10333

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920463

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium.

Authors:  P Cejas; M A García-Cabezas; E Casado; J Barriuso; J A Fresno; E Díaz; C Belda-Iniesta; J Castro; E Espinosa; P Zamora; J Feliu; A Redondo; D A Hardisson; M González-Barón
Journal:  Clin Transl Oncol       Date:  2005-07       Impact factor: 3.405

2.  Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Authors:  Pamela L Crowell; C Max Schmidt; Michele T Yip-Schneider; Jesse J Savage; Dean A Hertzler; William O Cummings
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Oral dysplasia: biomarkers, treatment, and follow-up.

Authors:  Paul Nankivell; Hisham Mehanna
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

4.  Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.

Authors:  B Shpitz; E Klein; G Buklan; D Neufeld; A Nissan; H R Freund; M Grankin; J Bernheim
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

5.  3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer.

Authors:  Kodagahalli Sathya Rakesh; Swamy Jagadish; Kyathegowdanadoddi Srinivas Balaji; Farhan Zameer; Toreshettahally Ramesh Swaroop; Chakrabhavi Dhanajaya Mohan; Shankar Jayarama; Kanchugarakoppal Subbegowda Rangappa
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

6.  Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.

Authors:  Jason A Zell; Argyrios Ziogas; Leslie Bernstein; Christina A Clarke; Dennis Deapen; Joan A Largent; Susan L Neuhausen; Daniel O Stram; Giske Ursin; Hoda Anton-Culver
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

Review 7.  Aspirin use and the risk of gastric cancer: a meta-analysis.

Authors:  Ping Yang; Yong Zhou; Bo Chen; Hong-Wei Wan; Gui-Qing Jia; Hai-Long Bai; Xiao-Ting Wu
Journal:  Dig Dis Sci       Date:  2009-08-12       Impact factor: 3.199

Review 8.  Chemoprevention of colorectal cancer.

Authors:  Michaela Lang; Christoph Gasche
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

9.  Feasibility of recruitment to an oral dysplasia trial in the United Kingdom.

Authors:  Paul Nankivell; Janet Dunn; Michael Langman; Hisham Mehanna
Journal:  Head Neck Oncol       Date:  2012-06-25

Review 10.  Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity.

Authors:  L McEvoy; D F Carr; M Pirmohamed
Journal:  Front Pharmacol       Date:  2021-06-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.